Could a single iron infusion help heart failure patients feel better?

NCT ID NCT07643818

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study tests whether a single intravenous dose of iron (ferric derisomaltose) can improve symptoms, exercise ability, and quality of life in 150 adults with a type of heart failure called HFpEF who also have iron deficiency. Participants will receive either the iron infusion or a placebo and be followed for 12 weeks. The main goal is to see if they can walk farther in six minutes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ferric derisomaltose (Monofer) given as a single intravenous infusion
What this could lead to
If it works, this could provide a simple treatment to improve daily life and physical ability for people with a common type of heart failure.
What could go wrong
This is a small, early-phase trial (150 people) that hasn't started yet. It may not show clear benefit, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Jersey General Hospital

    Saint Helier, Jersey

More trials for these conditions

Other studies related to the condition(s) this trial covers.